Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-01-10
2009-12-29
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S135100, C424S141100, C424S143100, C514S002600, C514S012200, C530S350000
Reexamination Certificate
active
07638126
ABSTRACT:
Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
REFERENCES:
patent: 5925735 (1999-07-01), Baumgartner et al.
patent: 7064186 (2006-06-01), Sprecher et al.
patent: 7425325 (2008-09-01), Sprecher et al.
patent: 7459293 (2008-12-01), Sprecher et al.
patent: 7507795 (2009-03-01), Sprecher et al.
patent: 7514077 (2009-04-01), Yao et al.
patent: 2003/0096339 (2003-05-01), Sprecher et al.
patent: 2003/0215838 (2003-11-01), Sprecher et al.
patent: 2006/0182743 (2006-08-01), Bilsborough
patent: 2006/0188499 (2006-08-01), Leung et al.
patent: 2006/0188500 (2006-08-01), Leung et al.
patent: 2006/0228329 (2006-10-01), Brady et al.
patent: 2006/0275296 (2006-12-01), Siadak et al.
patent: 2007/0048222 (2007-03-01), Sprecher et al.
patent: 2007/0048223 (2007-03-01), Sprecher et al.
patent: 2007/0048831 (2007-03-01), Sprecher et al.
patent: 2007/0048832 (2007-03-01), Sprecher et al.
patent: 2007/0048833 (2007-03-01), Sprecher et al.
patent: 2007/0048834 (2007-03-01), Sprecher et al.
patent: 2007/0048835 (2007-03-01), Sprecher et al.
patent: 2007/0049530 (2007-03-01), Sprecher et al.
patent: 2007/0140963 (2007-06-01), Sprecher et al.
patent: 2007/0140964 (2007-06-01), Sprecher et al.
patent: 04/003140 (2004-01-01), None
patent: 08/028192 (2008-03-01), None
Dillon et al. (2004). Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nature Immunology. 5(7):752-760.
Bilsborough et al. (2006). IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. The Journal of Allergy Clinical Immunology. 117(2):418-425.
Miller, G. (2002). Breaking down barriers. Science. 297:1116-1118.
Pettit et al. (1998). The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals. Trends in Biotechnology. 16: 343-349.
Felderhoff-Muesser et al. (2005). IL-18: a key player in neuroinflammation and neurodegeneration? Trends in Neurosciences. 28(9):487-493.
Riken, 1999, (GenBank Acc. No. AV040649).
Riken, 1999, (GenBank Acc. No. AV044404).
Riken, 1999, (GenBank Acc. No. AV268991).
Riken, 1999, (GenBank Acc. No. AV280874).
National Cancer Institute, 1997, (GenBank Ace. No. BF152807).
Riken, 2001, (GenBank Acc. No. BB610257).
Riken, Accession No. AK005939, 1999.
Riken, Accession No. AK005939, 2001.
National Institutes of Health, 1999, (GenBank Acc. No. CA464033).
Riken, 2002, (GenBank Acc. No. BY706076).
Washington University School of Medicine, 2002, (GenBank Acc. No. CF105870).
RZPD Deutsches Ressourcenzentrum fuer Genomforschung GmbH, 2003, (GenBank Acc. No. BX639332).
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 3482986, Jan. 11, 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 16727183, Feb. 24, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 10456006, Mar. 14, 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 8480322, Jan. 13, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 49775248, Oct. 5, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 10005090, Mar. 10, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 20965871, Mar. 16, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 44835892, Sep. 20, 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 50734527, Oct. 6, 2001.
Sanger Center, Mouse Public Genomic Sequence TDB 40505897, Aug. 31, 2001.
Sanger Center, Mouse Public Genomic Sequence TDB 1021719, Jan. 4, 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 22973884, Apr. 16, 2001.
Abstract from the American Society of Human Genetics Meeting, Nov. 7, 2003 on Gene Structure and Function.
EMBL Accession No. AC048338, Apr. 2000.
EMBL Accession No. AA381907, Apr. 1997.
Dillon et al., “Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice,” Nature Immunology 5(7):752-760, Jul. 2004.
Bilsborough et al., “IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T-cells in patients with atopic dermatitis”, Journal of Allergy and Clinical Immunology, Mosby - Yearly Book, Inc., US 117(2): 418-425, Feb. 7, 2006.
Sonkoly et al., “IL-31: A new link between t-cells and pruritus in atopic skin inflammation”, Journal of Allergy and Clinical Immunology, Mosby - Yearly Book, Inc., US 117(2): 411-417, Feb. 2006.
Takaoka A. et al., “Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis”, Experimental Dermatology, 15 (3): 161-167, Mar. 2006.
Takaoka A. et al., “Expression of IL-3I gene transcript in NC/Nga mice with atopic dermatitis”, European Journal of Pharmacology, Amsterdam, NL, 516 (2): 180-181, May 31, 2005.
Goding, J.W., Journal of Immunological Methods vol. 39: 285-308, 1980.
Brune et al., Hautarzt 55: 1130-1136, 2004.
Ständer et al., Hautarzt 54: 413-417, 2003.
Claudy, A., Pathologie et Biologie, L'Expansion Scientifique Francaise, Paris, FR 44(10): 888-894, 1996.
Leung, D. et al., “New insights into atopic 2004. dermititis”,Journal of Clinical Investigation 113(5):651-657, Mar. 2004.
Boguniewies, M. et al., “Atopic dermititis”,J Allergy Clin Immunol, 117(2):S475-S480, Feb. 2006.
Castellani, M.L. et al., “Interleukin-31: A new cytokine involved in inflammation of the skin”,Journal of Immunopathology and Pharmacology, 19(1):1-4, Jan. 13, 2006
“Monoclonal Anti-human IL-31 Antibody”, R&D Systems, Inc., Apr. 18, 2006.
Presta et al.,Advanced Drug Delivery Reviews 58(5-6): 640-656, 2006.
Neis et al., “Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis,” Journal of Allergy and Clinical Immunology, 118(4): 930-937, Oct. 1, 2006.
Bilsborough et al., U.S. Appl. No. 12/239,107, filed Sep. 26, 2008.
Bilsborough et al., U.S. Appl. No. 11/972,596, filed Jan. 10, 2008.
Sprecher et al., U.S. Appl. No. 12/193,665, filed Aug. 18, 2008.
Conti et al., “Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32)” Autoimmunity Reviews 6(3): 131-137, 2007.
EMBL Accession No. AK005939, Feb. 8, 2001.
Wills-Karp, M., “The gene encoding inerleukin-13: a susceptibility locus for asthma and related traits,” Respiratory Research, 1(1): 19-23, Jul. 17, 2000.
U.S. No. 11/430,066, Non-Final Rejection mailed May 1, 2008.
Perrigoue et al., “IL-31-IL,-31R interactions negatively regulate type 2 inflammation in the lung”, J Exp Med. Mar. 19, 2007;204(3):481-7. Epub Mar. 12, 2007. PMID: 17353366 Publisher: J Exp Med.
Ip et al., “Interleukin-31 induces cytokine and chernokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response”. Immunology. Jul 11, 2007;. PMID: 17627770 Publisher: Immunology.
Dambacher et al., “Orphan class I cytokine receptor Zcytor17 is upregulated in activated monocytes and T cells”, (W-2-4), Gut. Apr 20, 2007;. PMID: 17449633 Publisher: Gut.
Hammond et al., “Orphan class I cytokine receptor Zcytor17 is upregulated in activated monocytes and T cells”, (W-2-4), S48, Sep. 2002.
Yao et al., U.S. Appl. No. 12/395,095, filed Feb. 27, 2009.
Dillon et al., “Transgenic mice overexpressing a novel cytokine (IL-31) develop a severe pruritic skin phenotype resembling atopic dermatitis,” European Cytokine Network 14(3): 81, 2003.
Bilsborough Janine
Yao Yue
Adams Robyn
Landes Jeffrey E.
Lockard Jon M
Saoud Christine J
Walsh Brian J.
LandOfFree
Methods of treating pain and inflammation in neuronal tissue... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating pain and inflammation in neuronal tissue..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating pain and inflammation in neuronal tissue... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079481